April 19, 2019
The idea was simple: find the faulty signals that drive cancerous growth in cells, and block them. But what University of North Carolina Lineberger Comprehensive Cancer Center researcher Pengda Liu, PhD, has discovered, when it comes to cancer, even straightforward concepts can become complicated. “When you find a target and inhibit it, you find the …
March 12, 2019
Basal-like breast cancer is the most aggressive and difficult-to-treat subtype of breast cancer, and it largely overlaps with the triple-negative classification of the disease. Patients are in dire need of improved therapies that attack the underlying cellular features of these types of breast cancer. Now scientists at the University of North Carolina Lineberger Comprehensive Cancer …
February 11, 2019
UNC Lineberger awarded grants to 14 scientists and research teams in the fall grant awards cycle. Applications for the next round of funding will be due March 15.
January 31, 2019
University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators have discovered how a cellular signal that’s abnormally hyperactive in cancer can be deactivated. In the journal Cell Reports, UNC Lineberger’s M. Ben Major, PhD, and colleagues published a paper on how the WNT signaling pathway is regulated. WNT proteins increase tumor onset, growth …
January 29, 2019
University of North Carolina Lineberger Comprehensive Cancer Center scientist Antonio “Tony” Amelio, PhD, is not necessarily looking for the “smoking gun” of cancer biology, or one single cause of cancer. Instead, he’s looking into how a family of newly described proteins involved in the cellular stress response can cause a complex ripple effect of changes …
October 5, 2018
In the journal Molecular Cell, researchers led by UNC Lineberger's G. Greg Wang, PhD, and H. Shelton Earp, MD, describe the role of a protein variant called androgen receptor variant 7 (AR-V7), which is an alternative form of the androgen receptor that plays a key role in prostate cancer development and treatment.
July 19, 2018
In a study published in the journal Science, researchers led by UNC Lineberger's Qing Zhang, PhD, suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer.
